1.
Transfusion of irradiated red blood cell units with a potassium adsorption filter: A randomized controlled trial
Cid J, Villegas V, Carbasse G, Alba C, Perea D, Lozano M
Transfusion. 2016;56((5):):1046-51
Abstract
BACKGROUND The irradiation of red blood cells (RBCs) causes damage of the RBC membrane with increased potassium (K) leak during storage compared with nonirradiated RBC units of similar age. A previous in vitro study showed a mean reduction of K of 94 +/- 5% with a potassium adsorption filter (PAF). STUDY DESIGN AND METHODS A prospective, single-center, nonblinded, randomized controlled trial (RCT) was designed to evaluate the safety and efficacy of transfusing irradiated RBC units with the PAF. Patients 18 years of age or older who received irradiated RBC units due to chemotherapy-induced anemia were randomly assigned to receive irradiated RBC units with the PAF (PAF group) or with the standard blood infusion set (control group). Primary outcome measures were safety and efficacy of the PAF (absolute change in hemoglobin [Hb] and K, respectively, in patient's blood values after transfusing the irradiated RBC units with or without the PAF). RESULTS A total of 63 irradiated RBC units were transfused to 17 patients in the control group, and a total of 56 irradiated RBC units were transfused to 13 patients in the PAF group. The absolute change of Hb (9.3 +/- 6.3 g/L vs. 8.1 +/- 5.8 g/L; p = 0.3) and the absolute change of K (-0.01 +/- 0.4 mmol/L vs. -0.01 +/- 0.3 mmol/L; p = 0.2) were comparable between the two groups of the trial. CONCLUSION The transfusion of 1 irradiated RBC unit with the PAF was as safe and efficacious as the transfusion of 1 irradiated RBC unit with the standard blood infusion set in patients with chemotherapy-induced anemia.
2.
A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion
Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, et al
British Journal of Haematology. 2011;153((3):):393-401.
Abstract
Bacteria in platelet components (PC) may result in transfusion-related sepsis (TRS). Pathogen inactivation of PC with amotosalen (A-PC) can abrogate the risk of TRS and hence facilitate storage to 7 d. A randomized, controlled, double-blinded trial to evaluate the efficacy and safety of A-PC stored for 6-7 d was conducted. Patients were randomized to receive one transfusion of conventional PC (C-PC) or A-PC stored for 6-7 d. The primary endpoint was the 1 h corrected count increment (CCI) with an acceptable inferiority of 30%. Secondary endpoints included 1- and 24-h count increment (CI), 24-h CCI, time to next PC transfusion, red blood cell (RBC) use, bleeding and adverse events. 101 and 100 patients received A-PC or C-PC respectively. The ratio of 1-h CCI (A-PC:C-PC) was 0·87 (95% confidence interval: 0·73, 1·03) demonstrating non-inferiority (P = 0·007), with respective mean 1-h CCIs of 8163 and 9383; mean 1-h CI was not significantly different. Post-transfusion bleeding and RBC use were not significantly different (P = 0·44, P = 0·82 respectively). Median time to the next PC transfusion after study PC was not significantly different between groups: (2·2 vs. 2·3 d, P = 0·72). Storage of A-PCs for 6-7 d had no impact on platelet efficacy.
3.
A multi-center study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (INTERCEPT) stored for 6 or 7 days prior to transfusion
Lozano M, Knutson N, Tardivel R, Cid J, Maymo R, Lof HM, Roddie HP, Pelly JP, Docherty AR, Sherman CD, et al
Vox Sanguinis. 2010;99((Suppl S1):):13. Abstract No. 3B-S07-03.
4.
Frequency of prophylactic transfusion failure: a novel outcome to evaluate platelet components stored more than 5 days
Lozano M, Knutson F, Tardivel R, Cid J, Maymó R, Löf H, Roddie H, Lin L, Corash L, Prowse C
Transfusion. 2010;50((Suppl 2):):25A-26A.. Abstract No. S54-030D.
5.
Oral iron and folic acid supplements in a preoperative autologous blood collection program: a randomized study
Cid J, Ortín X, Contreras E, Elies E
Medicina Clinica. 2005;124((18):):690-1.
Abstract
BACKGROUND AND OBJECTIVE We evaluated the capacity of oral iron with or without oral folic acid administration to improve the accomplishment of our scheduled preoperative autologous blood collection program in patients with baseline hemoglobin > 115 g/l. PATIENTS AND METHOD Patients were enrolled in a randomized trial. The control group received no vitamin supplements. The iron group received 105 mg of elemental iron daily p. o. The and iron+folate group received 105 mg of elemental iron daily and 5 mg of folic acid daily p. o. RESULTS Eighty-six percent of patients in the control group, 86% of patients in the iron group and 87% of patients in the iron+folate group accomplished our preoperative autologous blood collection program. CONCLUSION In our study, neither oral iron nor folic acid supplements enhanced the accomplishment of our preoperative autologous blood collection program in patients with baseline hemoglobin > 115 g/l.
6.
Vitamin supplements to accomplish a preoperative autologous blood collection program
Cid J, Ortin X, Mila R, Merino V, Contreras E, Elies E
Vox Sanguinis. 2004;87((Suppl 3):):55. Abstract No. P 2.3.
7.
Vitamin supplements to accomplish a preoperative autologous blood collection program
Cid J, Elies E
Transfusion. 2004;44((s1):):80A.. Abstract No. SP161.